We are experienced therapeutic professionals delivering expertise, effective leadership, and strategic operational services to immunology clinical studies.
Our experience in immunology spans early-phase development through successful regulatory submission. This solid experience affords us with a thorough understanding of the treatment communities and patient populations with many key immunology disorders.
We have conducted 100+ immunology studies in recent years in wide-ranging indications. Our successful record of managing immunology clinical development programs has resulted in the approval of five important drugs for which we provided critical services.
Value-added solutions in immunology
Our immunology therapeutic experts review each study proposal and develop recommendations to help our clients achieve their goals, and we have a number of tools to guide our programs:
Novel database analytics to facilitate strategic country and site selection
Country-focused approach to start-up activities and in-depth knowledge of regulatory considerations
Strong relationships with immunology sites, renowned experts, and leading investigators worldwide
An enrollment validation process that yields accurate assessments of site enrollment rates and facilitates patient identification
recruitment and retention
A dedicated patient access group that facilitates recruitment and retention services
Core areas of immunology expertise
In recent years, our clinical development experience has spanned 15 indications, including these core areas:
# Clinical Studies87
Target # Clinical Sites5,200+
Target # Clinical Patients27,200+
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
PRA Delivers Study Start-up Success
PRA was awarded a rheumatoid arthritis study contract based on our strategy for achieving first-patient-in (FPI) by the end of the calendar year.…
Targeting Patients In A Complex Phase II Rheumatoid Arthritis Study
Targeting Patients In A Complex Phase IIa Rheumatoid Arthritis Study.